SCHEMBL840253

SCHEMBL840253

FC(F)(F)C1CCCN(Cc2cccc(Br)n2)C1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.43
HTR7 P34969 1/20 0.42
FAAH O00519 1/20 0.40
GRM2 Q14416 2/20 0.39
MAPT P10636 1/20 0.38
PDE2A O00408 1/20 0.38
CXCR4 P61073 2/20 0.37
METTL3 Q86U44 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TEAD1 P28347 1/20 0.37
ACHE P22303 1/20 0.37
PDE10A Q9Y233 1/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL838790 0.83 FAAH (0.43) KMT2AMEN1SMN1; SMN2FAAHMAPT
SCHEMBL5345901 0.80 ALDH1A1 (0.55) KMT2AMEN1SMN1; SMN2FAAHMAPT
SCHEMBL840728 0.80 LMNA (0.53) KMT2AMEN1SMN1; SMN2FAAHMAPT
SCHEMBL2476534 0.79 TRPV3 (0.44) KMT2AMEN1GAAHTR7GRM2
SCHEMBL839038 0.76 FAAH (0.53) SMN1; SMN2FAAHMAPTCXCR4ACHE
SCHEMBL5337822 0.75 GAA (0.55) KMT2AMEN1GAASMN1; SMN2FAAH
SCHEMBL18998097 0.75 MEN1 (0.63) KMT2AMEN1GAAHTR7MAPT
SCHEMBL13374356 0.73 FAAH (0.46) KMT2AFAAHCXCR4L3MBTL1ACHE
SCHEMBL5337564 0.71 ALDH1A1 (0.64) KMT2AMEN1GAASMN1; SMN2NPSR1
SCHEMBL5346199 0.71 FAAH (0.52) KMT2AMEN1FAAHMAPTCXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143246-B2 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives MSD OSS B.V. (NL) 2012-03-27 US disclosed
EP-2373639-A1 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES N.V. Organon (NL) 2011-10-12 EP disclosed
US-20100144724-A1 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES N.V.ORGANON 2010-06-10 US disclosed
WO-2010063666-A1 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144724-A1 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES OPRD1, CNR1, CNR2 KMT2A 1921/4885MEN1 2597/4885GAA 4867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.